No­var­tis CEO Vas Narasimhan's R&D up­date spot­lights next wave of drug stars as well as late-stage fa­vorites

As one of the biggest spenders in bio­phar­ma R&D, No­var­tis ex­ecs love to tout the scope of its late-stage pipeline, spot­light­ing the win­ners most like­ly to cre­ate block­buster rev­enue streams in the near fu­ture.

Build­ing on the 5 drug ap­provals the phar­ma gi­ant ex­pects to end the year with, No­var­tis CEO Vas Narasimhan — who’s done a slate of ac­qui­si­tions topped by the re­cent $9.7 bil­lion Med­Co buy­out — tapped the top emerg­ing drugs as:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER